Skip to main content
SpringerLink
Log in

4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Alvina K, Khodakhah K (2010) The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 30:7258–7268

    Article  PubMed  CAS  Google Scholar 

  2. Hausdorff JM (2005) Gait variability: methods, modeling and meaning. J Neuroeng Rehabil 2:19

    Article  PubMed  Google Scholar 

  3. Hausdorff JM (2007) Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking. Hum Mov Sci 26:555–589

    Article  PubMed  Google Scholar 

  4. Ilg W, Golla H, Thier P, Giese MA (2007) Specific influences of cerebellar dysfunctions on gait. Brain 130:786–798

    Article  PubMed  Google Scholar 

  5. Jahn K, Deutschlander A, Stephan T, Kalla R, Wiesmann M, Strupp M, Brandt T (2008) Imaging human supraspinal locomotor centers in brainstem and cerebellum. Neuroimage 39:786–792

    Article  PubMed  Google Scholar 

  6. Jodice C, Mantuano E, Veneziano L, Trettel F, Sabbadini G, Calandriello L, Francia A, Spadaro M, Pierelli F, Salvi F, Ophoff RA, Frants RR, Frontali M (1997) Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet 6:1973–1978

    Article  PubMed  CAS  Google Scholar 

  7. Lohle M, Schrempf W, Wolz M, Reichmann H, Storch A (2008) Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2—a video case report. Mov Disord 23:1314–1316

    Article  PubMed  Google Scholar 

  8. Mori S, Matsuyama K, Mori F, Nakajima K (2001) Supraspinal sites that induce locomotion in the vertebrate central nervous system. Adv Neurol 87:25–40

    PubMed  CAS  Google Scholar 

  9. Powell LE, Myers AM (1995) The Activities-specific Balance Confidence (ABC) Scale. J Gerontol A Biol Sci Med Sci 50A:M28–M34

    Article  PubMed  CAS  Google Scholar 

  10. Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S, van de Warrenburg BP, Durr A, Klockgether T, Fancellu R (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720

    Article  PubMed  CAS  Google Scholar 

  11. Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62:1623–1625

    PubMed  CAS  Google Scholar 

  12. Strupp M, Kalla R, Glasauer S, Wagner J, Hufner K, Jahn K, Brandt T (2008) Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog Brain Res 171:535–541

    Article  PubMed  Google Scholar 

  13. van de Warrenburg BP, Steijns JA, Munneke M, Kremer BP, Bloem BR (2005) Falls in degenerative cerebellar ataxias. Mov Disord 20:497–500

    Article  PubMed  Google Scholar 

  14. Walker ML, Austin AG, Banke GM, Foxx SR, Gaetano L, Gardner LA, McElhiney J, Morris K, Penn L (2007) Reference group data for the functional gait assessment. Phys Ther 87:1468–1477

    Article  PubMed  Google Scholar 

  15. Walter JT, Alvina K, Womack MD, Chevez C, Khodakhah K (2006) Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. Nat Neurosci 9:389–397

    Article  PubMed  CAS  Google Scholar 

  16. Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C (2005) Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing 34:614–619

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Judy Benson for copy editing the article. The work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG JA 1087/1-1) and the German Hertie Foundation.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital Munich, Campus Grosshadern, Marchioninistrasse 15, 81377, Munich, Germany

    Roman Schniepp, Nibal Ackl, Adrian Danek, Michael Strupp & Klaus Jahn

  2. Integrated Research and Treatment Center for Vertigo, Balance and Ocular Motor Disorders: IFB(LMU), University of Munich, Marchioninistrasse 15, 81377, Munich, Germany

    Roman Schniepp, Thomas Brandt, Michael Strupp & Klaus Jahn

  3. Graduate School of Systemic Neurosciences, University of Munich, Munich, Germany

    Max Wuehr

  4. Institute of Clinical Neurosciences, University of Munich, Marchioninistrasse 15, 81377, Munich, Germany

    Thomas Brandt

Authors
  1. Roman Schniepp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Max Wuehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nibal Ackl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adrian Danek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Brandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Strupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Klaus Jahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roman Schniepp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schniepp, R., Wuehr, M., Ackl, N. et al. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J Neurol 258, 1708–1711 (2011). https://doi.org/10.1007/s00415-011-5987-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-011-5987-z

Keywords

Search

Navigation